Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I PA8140-102 Bioavailability Study: pharmacokinetics of aspirin/omeprazole [PA 8140] vs enteric-coated aspirin

X
Trial Profile

Phase I PA8140-102 Bioavailability Study: pharmacokinetics of aspirin/omeprazole [PA 8140] vs enteric-coated aspirin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Embolism and thrombosis; Gastric ulcer; NSAID-induced ulcer
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 09 Jan 2017 According to an Aralez Pharmaceuticals Inc. media release, the company has submitted a Marketing Authorization Application (MAA) to the EMA for PA10040 (YOSPRALA) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers based on results from three trials (CTPs 700036117, 700048158 and 700225598).
    • 15 Mar 2016 According to an Aralez Pharmaceuticals media release, the company has resubmitted to the US FDA the NDA for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
    • 29 May 2013 The US FDA has accepted for review POZEN's NDA for PA 32540/PA 8140, according to a POZEN media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top